Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

“[MCRPC is] like a car that keeps moving, even though you’re pushing on the brakes in the form of hormone therapy.” It’s common for hormone therapy, known as androgen deprivation therapy ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s NVS Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of patients ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.

Novartis (NVS) announced that the Food and Drug Administration approved Pluvicto for patients with prostate-specific membrane antigen-positive ...

The randomised trial uses a companion lipid biomarker test, PCPro, to identify mCRPC patients with a poor prognosis who may benefit from the combination. In the trial, 200 eligible subjects will ...

FDA expands Pluvicto indication to adults with PSMA+ metastatic castration-resistant prostate cancer previously treated with ...

reduced the fracture rate in the EORTC 1333/PEACE-3 trial comparing radium-223 plus enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC ...